Lonza

Pharma & Biotech

your next IND...

Let's speed it up together.

ibex™ | design

The demand for biopharmaceutical products is continuously growing to serve the needs of an aging global population and the prevalence of chronic diseases. At the same time, the environment for biopharma companies is complex and challenging, with novel regulatory pathways, requirements to accelerate patient access, and rising competition.

Speed with confidence in delivery

To help you navigate through uncertainty, de-risk and accelerate your clinical development, we have created Ibex™ Design, an innovative CDMO service offering for antibodies and antibody-like molecules.

Ibex™ Design includes a pioneering gene-to-vial package, delivering drug product for your clinical trials, within 12 months[1]. Also included are submission-ready CMC data for your IND/IMPD and a manufacturing slot reserved for your clinical resupply needs.

To take you to IND-ready in 12 months, Ibex™ Design relies on:

- A proven platform process powered by our GS Gene Expression System®
- A highly automated facility that drives timeline reductions and efficiency gains
- Single-use technology that reduces manufacturing time
- PAT[2] and novel drying technologies that reduce lyophilization time
- Integrated drug substance and drug product development capabilities that support a holistic development strategy with the endpoint in mind

Gene to IND timelines (in months)

Ibex™ Design, a gene-to-vial package that enables you to consolidate your product's lifecycle at a single site, under one quality system.



* based on publicly available information

ibex™ | design develop dedicate

Lonza
Pharma & Biotech

Game changing business model

Ibex™ Design increases predictability by offering you a package with an output commitment[3] and by providing flexibility for your clinical resupply. The business model is particularly adapted to accompany your business transformation going from development to clinical stage. The increased predictability can help with your next funding.

Consolidated supply chain

Ibex™ Design offers drug substance and drug product capabilities in one location. This enables you to manage your product's lifecycle at a single site, under one quality system. In addition, it offers a holistic and tightly integrated product development concept, where we support your journey to clinical production and beyond.

Faster, without quality compromises

With Ibex™ Design you will benefit from both an accelerated development process and a high-quality end product. This means that you will be well positioned to meet your next project milestone and your business goals. This offering leverages more than 30 years track record of innovation in biologics and extensive preclinical/IND experience.

Your next clinical stage... let's go there together

As your project progresses to later clinical stages, you can conveniently leverage the capabilities of **Ibex™ Develop** in the same building – no need for tech transfer to a different site. Benefit from our proven GS Gene Expression System® bioprocess platform and from a holistic development strategy with the endpoint in mind.



Ibex™ Solutions consist of three CDMO offerings: Ibex™ Design, Ibex™ Develop and Ibex™ Dedicate that span the complete biopharmaceutical lifecycle – from preclinical to commercial stages, from drug substance to drug product, all in one location. The variety of solutions offerings provide the flexibility of a complete program – from gene to drug product, or the option to drop in at a later stage depending where you are in your journey.

Explore how Ibex™ Solutions can help you take your next drug to the market more quickly with game changing business and operating models **www.ibex.lonza.com**

Contact us

USA +1 201 316 9200
Japan +81 (0)3 6264 0600
Rest of world +41 61 316 81 11
Email ibex@lonza.com

ibex.lonza.com

1. From receipt of the gene sequence. Subject to contractual terms and conditions.
2. PAT: Process Analytical Technology.
3. Subject to contractual terms and conditions.